Has Kyriakie Sarafoglou received payments from drug or device companies?

Yes. Drug and device makers reported $76,675 in general payments to Kyriakie Sarafoglou across 95 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kyriakie Sarafoglou did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kyriakie Sarafoglou come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kyriakie Sarafoglou

Pediatrics · Minneapolis, MNNPI 1902989486

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $60,080 of the $76,675 with a category attached, or 78.4%. Neurocrine Biosciences, Inc. accounts for 91.9% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $48,160, more than ten times the $1,286 reported in 2019. Among pediatrics clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$76,675in general payments, 2019–2025

Across 95 payments — averaging $807.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurocrine Biosciences, Inc.$70K
AstraZeneca$3K
Novo Nordisk AS$1K
Eton Pharmaceuticals, Inc.$932
Novo Nordisk Health Care AG$900
Novo Nordisk$200
plus $90 from 2 others

$1,484,266in research payments, 2019–2025

Across 150 payments — averaging $9895.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Neurocrine Biosciences, Inc.$1.2M
AstraZeneca$217K
Biomarin Pharmaceutical Inc.$29K

What the payments were for

Consulting fees$60,08078%
Speaking & faculty fees$1,3132%
Travel & lodging$10,65714%
Food & beverage$4,5856%
Education$400%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurocrine Biosciences, Inc.	74	$70,447
AstraZeneca	8	$2,820
Novo Nordisk AS	4	$1,286
Eton Pharmaceuticals, Inc.	4	$932
Novo Nordisk Health Care AG	1	$900
Novo Nordisk	2	$200
Biomarin Pharmaceutical Inc.	1	$50
Tolmar Pharmaceuticals, Inc.	1	$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,675 in reported general payments places this provider in the 95th percentile of 397 pediatrics providers in Minnesota.

See all pediatrics providers in Minnesota →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
StrensiqAsfotase Alfa	26	$1,381,311
GenotropinSomatropin	14	$26,692
Hydrocortisone	12	$236
ProgesteroneProgesterone, Micronized	12	$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AstraZenecaStrensiq	$2,820	$1,381,31126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 397 pediatrics providers in Minnesota.

Other pediatrics in Minneapolis

Gurumurthy Hiremath MallikarjunMinneapolis$56K
Chester WhitleyMinneapolis$40K
Charlotte HobbsMinneapolis$30K
Mark SchleissMinneapolis$29K
Erick Jimenez GranadosMinneapolis$18K
Claudia FoxMinneapolis$16K
Angela GoepferdMinneapolis$10K
Timothy CapecchiMinneapolis$8K
Sara ElsbeckerMinneapolis$5K
Amy GoldsteinMinneapolis$4K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →